Clinical Trials Browser

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Ovarian Epithelial, Glioblastoma, Mesothelioma, Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Neuroendocrine Tumors

NCT05126433 2025-02-28

JAZZ EMERGE201

Phase 2 Terminated

47 enrolled 16 charts

Tumor-Agnostic

Neoplasm Metastasis

NCT06496048 2024-12-12

Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC

Phase 3 Recruiting

180 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT04638491 2024-06-10

Safety Tolerability Pharmacokinetic and Preliminary Efficacy in Chinese Advanced Solid Tumors Patients

Phase 1 Completed

32 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT05101265 2023-11-27

Clinical Pharmacokinetic Study of Lurbinectedin in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Impairment

Phase 1 Unknown

24 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT02454972 2023-03-02

Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors

Phase 2 Completed

345 enrolled 34 charts 1 FDA

Other solid neoplasm

Advanced Solid Tumors

NCT02566993 2021-10-28

ATLANTIS

Phase 3 Completed

613 enrolled 46 charts

Thoracic

Small Cell Lung Carcinoma

NCT01525589 2020-09-25

A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer

Phase 2 Completed

111 enrolled 31 charts

Breast

Breast Neoplasms

NCT01831089 2020-04-10

Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors

Phase 1 Completed

69 enrolled 17 charts

BreastGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Small Cell Lung Carcinoma

NCT02421588 2020-04-03

CORAIL

Phase 3 Completed

442 enrolled 33 charts

Gynecologic

Ovarian Neoplasms

NCT01970540 2020-03-09

Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors

Phase 1 Completed

122 enrolled 19 charts

EndocrineNET

Neoplasms, Neuroendocrine Tumors

NCT02451007 2019-11-19

Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors

Phase 2 Completed

39 enrolled 11 charts

Other solid neoplasm

Solid Tumors

NCT01951157 2019-09-24

A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients

Phase 2 Completed

69 enrolled 28 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01980667 2017-01-26

Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors

Phase 1 Completed

41 enrolled

Tumor-Agnostic

Neoplasms

NCT02210364 2016-12-14

Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC).

Phase 1 Completed

81 enrolled

BreastGastrointestinal

Breast Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT01405391 2016-01-15

Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks

Phase 1 Completed

42 enrolled

GastrointestinalOther solid neoplasm

Major Advanced Solid Tumors Other Than Colorectal

NCT01314599 2015-11-05

Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome

Phase 1 Completed

45 enrolled

Other hematologic neoplasm

Leukemia

NCT00877474 2015-11-04

Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors

Phase 1 Completed

30 enrolled

Other solid neoplasm

ADVANCED SOLID TUMORS

NCT01970553 2015-04-01

Escalating Doses of PM01183 in Combination With Gemcitabine in Patients With Specific Unresectable Solid Tumors

Phase 1 Completed

47 enrolled

Tumor-Agnostic

Neoplasms